About the job
About Acadia Pharmaceuticals
Acadia Pharmaceuticals focuses on turning scientific discoveries into meaningful treatments for underserved communities affected by neurological and rare diseases. The company’s commercial portfolio includes the first and only FDA-approved therapies for Parkinson’s disease psychosis and Rett syndrome. Acadia continues to advance a diverse pipeline, with mid- and late-stage programs for Alzheimer’s disease psychosis and Lewy body dementia psychosis, as well as early-stage efforts aimed at additional unmet needs. The team is committed to making a real difference in patients’ lives.
Location and Work Model
This position may be based in San Diego, CA, San Francisco, CA, or Princeton, NJ. Acadia offers a hybrid work model.
Role Overview
The Executive Director of Translational Sciences leads the design and execution of disease and drug mechanism of action (MoA) studies that advance therapeutics through clinical development. This position requires deep expertise in translational sciences and hands-on experience in rare diseases. Strong leadership and mentoring skills are essential, as well as a thorough understanding of clinical biomarker development and the full drug development process from discovery through late-stage clinical trials.
Success in this role depends on the ability to translate complex biological concepts and data into clear, actionable insights. The Executive Director must also demonstrate a record of effective cross-functional collaboration throughout the drug development process.
